http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View More Recent Stories
-
Telix Pharmaceuticals Announces Licence Agreement with Lilly for Olaratumab
-
Commercial Launch: Illuccix® Now Available to Order in the United States
-
Change of Composition of the Telix Board of Directors
-
New Video Series "PSMA PET/CT TODAY" Discusses the Future of Prostate Cancer Care with Leading Experts
-
Telix Granted FDA Orphan Drug Designation for Bone Marrow Conditioning Treatment
-
Telix Advances Development of Glioblastoma Therapy Program
-
Telix Radiopharmaceutical Production Facility Buildout Commences
-
ZIRCON Phase III Kidney Cancer Imaging Study Completes Target Enrolment
-
Telix and SHINE partner for Lutetium-177 Supply
-
Telix Expands Lutetium-177 Network with Eckert & Ziegler Clinical Supply Agreement
-
First Patient Dosed in ProstACT Program for Prostate Cancer Therapy
-
Telix Collaborates with Olivia Newton-John Cancer Research Institute on Brain Cancer Imaging Study
-
FDA Approves Telix’s Prostate Cancer Imaging Product, Illuccix®
-
Illuccix® Granted Use Authorisation for Prostate Cancer Imaging in Brazil
-
Australian TGA Approves Illuccix® for Prostate Cancer Imaging
-
IPAX-1 Late Breaking Oral Presentation at the Congress of Neurological Surgeons (CNS) Meeting
-
First Cyclotron Removed from Seneffe Production Facility by SCK CEN
-
First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer
-
Second Industry Body Updates Guidance for Use of PSMA PET Imaging
-
NCCN Guidelines Updated to Include PSMA-PET Imaging
-
FDA Approves Phase II Kidney Cancer Therapy Study
-
Telix In-Licences Novel Tumour Microenvironment PET Tracer
-
Telix to Collaborate With Kettering Health on Diagnostic PSMA Imaging & Targeting Theranostics
-
Michael Didocha Joins Telix as Chief Financial Officer, Americas
-
Lightpoint Medical and Telix Pharmaceuticals Announce Strategic Collaboration Agreement
-
Telix Expands Prostate Cancer Activity with GenesisCare Collaboration
-
Two New Studies to Explore Telix Assets in Breast Cancer Theranostics
-
Telix and Merck KGaA, Darmstadt, Germany, to Commence Pan-Cancer Clinical Combination Studies
-
Telix’s TLX66 in Phase II Academic Study of Pediatric Leukemia
-
First Patient Dosed in CUPID Study of Telix’s Targeted Alpha Therapy Candidate for Prostate Cancer
-
First Patient Dosed in Clinical Study of TLX250-CDx in Bladder Cancer
-
Telix Pharmaceuticals and Applied Radiology Launch TelixU Medical Education Platform Focused on Radiopharmaceutical Research
-
Telix Launches “Gallium Wave” Awareness Website
-
Telix to Present at the 2021 Jefferies Virtual Healthcare Conference
-
Cardinal Health and Telix Launch Gallium Awareness Campaign With Release of White-Paper: “Moving Beyond the Myth”
-
TLX66 Meets Study Objectives in Patients with AL Amyloidosis
-
Telix Commences Phase III Clinical Trial of Prostate Cancer Therapy
-
Telix Pharmaceuticals and Grand River Aseptic Manufacturing Complete Agreement for Commercial Manufacturing of Illuccix®
-
ITM Enters Global Supply Agreements with Telix Pharmaceuticals for Clinical and Commercial Use of ITM’s n.c.a. Lutetium-177
-
First US Patients Dosed in Phase III ZIRCON Trial of Renal Cancer Imaging Product
-
ARTMS and Telix Pharmaceuticals Announce Successful Production of PSMA-11 with Cyclotron Produced ⁶⁸Ga from a Solid Target
-
Telix Pharmaceuticals Enters Strategic Collaboration with Varian Medical Systems for Advanced Prostate Imaging
-
Portland Investment Counsel Inc. Leads Investment in Telix Pharmaceuticals Limited via Private Placement

